The abstract is read at the publisher; the summary is JClub's.
Pain-indicated transdermal or buccal buprenorphine prescribing in U.S. adults rose from 53.59 to 78.04 recipients per 100,000 from 2017–2025, with 5.04% average annual growth.
- Why it matters: National trends and state-level policy differences for pain-indicated buprenorphine have not been assessed together, nor whether Medicaid patterns track all-payer prescribing.
- What they did: Using 2017–2025 prescription claims for 867,591 adults across 888 three-digit ZIP code areas, the study modeled annual recipients per 100,000 with a hierarchical Bayesian approach and reviewed policies in 50 states plus D.C.
- The result: Growth varied by state—e.g., Minnesota 25.43% and Mississippi -2.96% annualized—and Identifiable-Medicaid prescribing grew 3.10% nationally, not consistently matching all-payer trends.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.